Ardea Biosciences Says Phase I HIV Drug Trial Success
Posted on: Thursday, 6 September 2007, 06:14 CDT
Ardea Biosciences has successfully completed Phase I trials of its investigational HIV drug, which the company said showed potent antiviral activity.
The trial involved single-ascending-dose, multiple-ascending-dose, food-effect, and drug-interaction studies evaluating RDEA806 is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) for the potential treatment of HIV infection. Based on preclinical and clinical studies to date, Ardea believes that RDEA806 possesses several attractive attributes.
These include: potent antiviral activity against a wide range of HIV viral isolates; the potential to be administered in a patient-friendly, oral dosing regimen; limited pharmacokinetic interactions with other drugs; and the ability to be co-formulated with other HIV antiviral drugs.
"We are very encouraged by our Phase I clinical trial results in healthy volunteers. Based on these results, we plan to initiate a phase IIa proof-of-concept study of RDEA806 in HIV-infected patients before the end of this year, the results of which may be available by the first quarter of 2008. Assuming positive results, a larger phase IIb study in HIV-infected patients could start in the second quarter of 2008," said Barry Quart, president and CEO of Ardea.
Source: Datamonitor
Related Articles
- Progenics Reports Positive Interim Phase 2 Results for Two Dosage Forms of Novel HIV Therapy PRO 140
- ThermoDox(R) Liver Cancer Study Phase I Results to Be Presented at ILCA Conference 2008
- QuantRx Reports Positive Phase I Results of Myocardial Imaging Tracer
- NuPathe Reports Positive Phase I Results for NP101, a Novel Transdermal Patch for Acute Migraine
- Liver Phase I Results Presented at WCIO 2008 & Best of ASCO(R)
- Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients With Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
- Amicus Announces Positive Phase I Results for Pompe Disease Drug
- Aeterna Phase I Results Support Cancer Compound
- Medarex and PharmAthene Announce Phase I Results of Anthrax Therapeutic Valortim(TM)
- FibroGen Reports Phase 1 Results of Investigational Oral Anemia Therapy, FG-2216, and New Data From Phase 2A Study in Anemic Chronic Kidney Disease Patients
 |
 |
User Comments (0)
RSS Feeds